The use of therapeutic peptides to target and to kill cancer cells.
暂无分享,去创建一个
A. Khaled | J. Perez | R. Boohaker | M. Lee | P. Vishnubhotla | J M Perez | R J Boohaker | M W Lee | P Vishnubhotla | A R Khaled | Michael W. Lee | Jesus Manuel Perez | J. M. Perez
[1] S. Korsmeyer,et al. BAX-dependent transport of cytochrome c reconstituted in pure liposomes , 2000, Nature Cell Biology.
[2] G. Diamond,et al. Isolation and Characterization of Pleurocidin, an Antimicrobial Peptide in the Skin Secretions of Winter Flounder* , 1997, The Journal of Biological Chemistry.
[3] J. Mai,et al. A proapoptotic peptide for the treatment of solid tumors. , 2001, Cancer research.
[4] Jingqiu Cheng,et al. Enhancement of cytotoxicity of antimicrobial peptide magainin II in tumor cells by bombesin-targeted delivery , 2011, Acta Pharmacologica Sinica.
[5] M. Stöckle,et al. Antimicrobial peptides of the Cecropin-family show potent antitumor activity against bladder cancer cells , 2008, BMC urology.
[6] E. Ruoslahti,et al. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. , 1998, Science.
[7] O. Olopade,et al. Overexpression of BCL-x protein in primary breast cancer is associated with high tumor grade and nodal metastases. , 1997, The cancer journal from Scientific American.
[8] C. Bucana,et al. Elevated expression of phosphatidylserine in the outer membrane leaflet of human tumor cells and recognition by activated human blood monocytes. , 1991, Cancer research.
[9] Kristian Pietras,et al. High interstitial fluid pressure — an obstacle in cancer therapy , 2004, Nature Reviews Cancer.
[10] D. Engelman,et al. Targeting acidic diseased tissue: New technology based on use of the pH (Low) Insertion Peptide (pHLIP). , 2009, Chimica oggi.
[11] D. Noonan,et al. Cell delivery of Met docking site peptides inhibit angiogenesis and vascular tumor growth , 2010, Oncogene.
[12] P. Colman,et al. BCL-2 family antagonists for cancer therapy , 2008, Nature Reviews Drug Discovery.
[13] G. Gillet,et al. Bax-derived membrane-active peptides act as potent and direct inducers of apoptosis in cancer cells , 2011, Journal of Cell Science.
[14] S. Batra,et al. Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells , 2010, Oncogene.
[15] Orlando L. Sánchez-Muñoz,et al. A lipocentric view of peptide-induced pores , 2011, European Biophysics Journal.
[16] D. Cheresh,et al. Requirement of vascular integrin alpha v beta 3 for angiogenesis. , 1994, Science.
[17] Y. Shai,et al. Host defense peptides as new weapons in cancer treatment , 2005, Cellular and Molecular Life Sciences CMLS.
[18] Derek W. Yecies,et al. Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. , 2010, Blood.
[19] Erkki Ruoslahti,et al. Tissue-penetrating delivery of compounds and nanoparticles into tumors. , 2009, Cancer cell.
[20] M. Bibby,et al. Preliminary experimental anticancer activity of cecropins. , 1994, Peptide research.
[21] E. Solary,et al. Human defensins as cancer biomarkers and antitumour molecules. , 2009, Journal of proteomics.
[22] H. Maeda,et al. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.
[23] A. M. van der Bliek,et al. Multidrug resistance phenotype of human BRO melanoma cells transfected with a wild-type human mdr1 complementary DNA. , 1990, Cancer research.
[24] S. Chan,et al. Effects of the anti-bacterial peptide cecropin B and its analogs, cecropins B-1 and B-2, on liposomes, bacteria, and cancer cells. , 1997, Biochimica et biophysica acta.
[25] D. Andrews,et al. Still embedded together binding to membranes regulates Bcl-2 protein interactions , 2010, Oncogene.
[26] Nico Tjandra,et al. Structure of Bax Coregulation of Dimer Formation and Intracellular Localization , 2000, Cell.
[27] I. Mingarro,et al. Peptides corresponding to helices 5 and 6 of Bax can independently form large lipid pores , 2006, The FEBS journal.
[28] London Wc,et al. De Novo Antimicrobial Peptides with Low Mammalian Cell Toxicity , 1996 .
[29] D. Hoskin,et al. Studies on anticancer activities of antimicrobial peptides. , 2008, Biochimica et biophysica acta.
[30] T. Kaku,et al. Effect of defensin peptides on eukaryotic cells: primary epithelial cells, fibroblasts and squamous cell carcinoma cell lines. , 2004, Journal of dermatological science.
[31] C. Scott,et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. , 2006, Cancer cell.
[32] Hao Xiong,et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] A. García-Sáez,et al. Role of membrane lipids for the activity of pore forming peptides and proteins. , 2010, Advances in experimental medicine and biology.
[34] D. Engelman,et al. Energetics of peptide (pHLIP) binding to and folding across a lipid bilayer membrane , 2008, Proceedings of the National Academy of Sciences.
[35] John Calvin Reed,et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. , 2006, Cancer cell.
[36] J. Barker,et al. Antibiotic magainins exert cytolytic activity against transformed cell lines through channel formation. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[37] H. Kosmehl,et al. Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. , 2001, Cancer research.
[38] K. Yoshida,et al. Interaction of pleurocidin and its analogs with phospholipid membrane and their antibacterial activity. , 2001, The journal of peptide research : official journal of the American Peptide Society.
[39] Fionnuala T Lundy,et al. The cytotoxic effects of human neutrophil peptide-1 (HNP1) and lactoferrin on oral squamous cell carcinoma (OSCC) in vitro. , 2006, Oral oncology.
[40] M. Higashiyama,et al. High prevalence of bcl-2 oncoprotein expression in small cell lung cancer. , 1995, Anticancer research.
[41] D. Ribatti,et al. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. , 2003, Cancer research.
[42] Maurice Green,et al. Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein , 1988, Cell.
[43] S. Qian,et al. Structure of transmembrane pore induced by Bax-derived peptide: Evidence for lipidic pores , 2008, Proceedings of the National Academy of Sciences.
[44] Ø. Rekdal,et al. BMC Cancer BioMed Central Study protocol , 2008 .
[45] Xuan Huang,et al. RGD peptide-mediated chitosan-based polymeric micelles targeting delivery for integrin-overexpressing tumor cells , 2011, International journal of nanomedicine.
[46] A. Patrzykat,et al. Novel Antimicrobial Peptides Derived from Flatfish Genes , 2003, Antimicrobial Agents and Chemotherapy.
[47] T. Ganz,et al. Antimicrobial defensin peptides form voltage-dependent ion-permeable channels in planar lipid bilayer membranes. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[48] P. Cao,et al. Expression and Functional Characterization of Tumor-Targeted Fusion Protein Composed of NGR Peptide and 15-kDa Actin Fragment , 2010, Applied biochemistry and biotechnology.
[49] Chiara Brignole,et al. Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy. , 2006, Cancer research.
[50] W. Mackinnon,et al. Plasma membrane lipid composition of vinblastine sensitive and resistant human leukaemic lymphoblasts , 1988, International journal of cancer.
[51] M. Sentjurc,et al. Cell membrane fluidity and prognosis of lung cancer. , 2002, The Annals of thoracic surgery.
[52] E. Ruoslahti,et al. Targeted nanoparticle enhanced proapoptotic peptide as potential therapy for glioblastoma , 2011, Proceedings of the National Academy of Sciences.
[53] E. Snyder,et al. Treatment of Terminal Peritoneal Carcinomatosis by a Transducible p53-Activating Peptide , 2004, PLoS biology.
[54] H. Hammes,et al. Regulation of neovascularization by human neutrophil peptides (α‐defensins): a link between inflammation and angiogenesis , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[55] Vladimir P Torchilin,et al. Tat peptide-mediated intracellular delivery of pharmaceutical nanocarriers. , 2008, Advanced drug delivery reviews.
[56] W. Wilson,et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. , 2010, The Lancet. Oncology.
[57] V. Torchilin,et al. Intracellular delivery of nanoparticles with CPPs. , 2011, Methods in molecular biology.
[58] Hideyoshi Harashima,et al. Design of a dual-ligand system using a specific ligand and cell penetrating peptide, resulting in a synergistic effect on selectivity and cellular uptake. , 2010, International journal of pharmaceutics.
[59] Erkki Ruoslahti,et al. Anti-cancer activity of targeted pro-apoptotic peptides , 1999, Nature Medicine.
[60] Susan Chang,et al. Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery , 2011, Journal of Neuro-Oncology.
[61] J. Schneider,et al. Materials from peptide assembly: towards the treatment of cancer and transmittable disease , 2011, Current Opinion in Chemical Biology.
[62] N. Fujii,et al. Interactions of an antimicrobial peptide, magainin 2, with outer and inner membranes of Gram-negative bacteria. , 1997, Biochimica et biophysica acta.
[63] R. Gambrell,et al. Peptide targeting of platinum anti-cancer drugs. , 2009, Bioconjugate chemistry.
[64] E. Yavin,et al. Multiple Triphenylphosphonium Cations as a Platform for the Delivery of a Pro-Apoptotic Peptide , 2011, Pharmaceutical Research.
[65] D. Shin,et al. The cell penetrating ability of the proapoptotic peptide, KLAKLAKKLAKLAK fused to the N-terminal protein transduction domain of translationally controlled tumor protein, MIIYRDLISH. , 2011, Biomaterials.
[66] M. Yarmush,et al. Amphipathic peptide-based fusion peptides and immunoconjugates for the targeted ablation of prostate cancer cells. , 2007, Cancer research.
[67] Erkki Ruoslahti,et al. Coadministration of a Tumor-Penetrating Peptide Enhances the Efficacy of Cancer Drugs , 2010, Science.
[68] Young-Suk Choi,et al. Cell‐penetrating chitosan/doxorubicin/TAT conjugates for efficient cancer therapy , 2011, International journal of cancer.
[69] D. Hoskin,et al. Pleurocidin-family cationic antimicrobial peptides are cytolytic for breast carcinoma cells and prevent growth of tumor xenografts , 2011, Breast Cancer Research.
[70] Jijin Gu,et al. Self-aggregated pegylated poly (trimethylene carbonate) nanoparticles decorated with c(RGDyK) peptide for targeted paclitaxel delivery to integrin-rich tumors. , 2011, Biomaterials.
[71] S. Lowe,et al. Genetic analysis of chemoresistance in primary murine lymphomas , 2000, Nature Medicine.
[72] J. Gera,et al. Human neutrophil peptide defensins induce single strand DNA breaks in target cells. , 1991, Cellular immunology.
[73] D. Engelman,et al. pH-sensitive membrane peptides (pHLIPs) as a novel class of delivery agents , 2010, Molecular membrane biology.
[74] P. Bulet,et al. Antiviral and antitumor peptides from insects , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[75] S. Korsmeyer,et al. Activation of Apoptosis in Vivo by a Hydrocarbon-Stapled BH3 Helix , 2004, Science.
[76] M. Herlyn,et al. Experimental local therapy of human melanoma with lytic magainin peptides , 1995, International journal of cancer.
[77] T. Ganz,et al. In vitro tumor cell cytolysis mediated by peptide defensins of human and rabbit granulocytes. , 1986, Blood.
[78] M. Asslaber,et al. In search of a novel target — Phosphatidylserine exposed by non-apoptotic tumor cells and metastases of malignancies with poor treatment efficacy , 2011, Biochimica et biophysica acta.
[79] A. I. Arunkumar,et al. Crumpled structure of the custom hydrophobic lytic peptide cecropin B3. , 2001, European journal of biochemistry.
[80] A. Roberts,et al. Overcoming blocks in apoptosis with BH3-mimetic therapy in haematological malignancies , 2011, Pathology.
[81] Carl O. Pabo,et al. Cellular uptake of the tat protein from human immunodeficiency virus , 1988, Cell.
[82] John Calvin Reed,et al. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. , 1993, Blood.
[83] F. D. De Braud,et al. Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma , 2010, British Journal of Cancer.
[84] Hueih Min Chen,et al. The combined effects of antibacterial peptide cecropin A and anti-cancer agents on leukemia cells. , 2002, Anticancer research.
[85] S. Schwarze,et al. In vivo protein transduction: delivery of a biologically active protein into the mouse. , 1999, Science.
[86] M. Rhee,et al. Mechanism of Uptake of C105Y, a Novel Cell-penetrating Peptide* , 2006, Journal of Biological Chemistry.
[87] M. Zasloff,et al. Magainins, a class of antimicrobial peptides from Xenopus skin: isolation, characterization of two active forms, and partial cDNA sequence of a precursor , 1987 .
[88] E. Ruoslahti,et al. Peptides selected for binding to clotted plasma accumulate in tumor stroma and wounds. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[89] Zhe Wang,et al. APD: the Antimicrobial Peptide Database , 2004, Nucleic Acids Res..
[90] A. Petros,et al. Solution structure of the antiapoptotic protein bcl-2 , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[91] G. Sherbet. Membrane fluidity and cancer metastasis. , 1989, Experimental cell biology.
[92] M. Zasloff,et al. Anticancer efficacy of Magainin2 and analogue peptides. , 1993, Cancer research.
[93] David L. Vaux,et al. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells , 1988, Nature.
[94] D. Engelman,et al. Mechanism and uses of a membrane peptide that targets tumors and other acidic tissues in vivo , 2007, Proceedings of the National Academy of Sciences.
[95] Junying Yuan,et al. Solution Structure of BID, an Intracellular Amplifier of Apoptotic Signaling , 1999, Cell.
[96] D. Hughes,et al. The Apoptotic Protein tBid Promotes Leakage by Altering Membrane Curvature* , 2002, The Journal of Biological Chemistry.
[97] H. Vogel,et al. Relative Spatial Positions of Tryptophan and Cationic Residues in Helical Membrane-active Peptides Determine Their Cytotoxicity* , 2011, The Journal of Biological Chemistry.
[98] D. Andrews,et al. BH3-only proteins: Orchestrators of apoptosis. , 2011, Biochimica et biophysica acta.
[99] D. Engelman,et al. Spontaneous, pH-dependent membrane insertion of a transbilayer alpha-helix. , 1997, Biochemistry.
[100] M. Mccarty,et al. Manipulating tumor acidification as a cancer treatment strategy. , 2010, Alternative medicine review : a journal of clinical therapeutic.
[101] U. Settmacher,et al. Discovery and identification of alpha-defensins as low abundant, tumor-derived serum markers in colorectal cancer. , 2005, Gastroenterology.
[102] Friedrich Paulsen,et al. Antitumor activity of the antimicrobial peptide magainin II against bladder cancer cell lines. , 2006, European urology.
[103] D. Green,et al. Minimal BH3 Peptides Promote Cell Death by Antagonizing Anti-apoptotic Proteins* , 2003, Journal of Biological Chemistry.
[104] H. Dosaka-akita,et al. Bcl-2 Expression in Non-Small Cell Lung Cancers: Higher Frequency of Expression in Squamous Cell Carcinomas with Earlier pT Status , 1999, Oncology.
[105] V. Torchilin,et al. “Smart” Drug Carriers: PEGylated TATp-Modified pH-Sensitive Liposomes , 2007, Journal of liposome research.
[106] R K Jain,et al. Transport of molecules, particles, and cells in solid tumors. , 1999, Annual review of biomedical engineering.
[107] M. Tsao,et al. Glypican-3 is overexpressed in lung squamous cell carcinoma, but not in adenocarcinoma , 2008, Modern Pathology.
[108] Michael J. McGuire,et al. A Peptide Selected by Biopanning Identifies the Integrin αvβ6 as a Prognostic Biomarker for Nonsmall Cell Lung Cancer , 2007 .
[109] T. Mikkelsen,et al. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[110] R Pasqualini,et al. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. , 2000, Cancer research.
[111] Sabrina Riedl,et al. Membrane-active host defense peptides – Challenges and perspectives for the development of novel anticancer drugs , 2011, Chemistry and physics of lipids.
[112] Eun Seong Lee,et al. A novel pH-responsive polysaccharidic ionic complex for proapoptotic D-(KLAKLAK)2 peptide delivery. , 2011, Chemical communications.
[113] T. Hambley,et al. Is anticancer drug development heading in the right direction? , 2009, Cancer research.
[114] Soon-ja Kim,et al. Effects of the synthetic coprisin analog peptide, CopA3 in pathogenic microorganisms and mammalian cancer cells. , 2012, Journal of microbiology and biotechnology.
[115] V. Torchilin,et al. "SMART" drug delivery systems: double-targeted pH-responsive pharmaceutical nanocarriers. , 2006, Bioconjugate chemistry.
[116] Joy Joseph,et al. Doxorubicin-induced apoptosis: Implications in cardiotoxicity , 2002, Molecular and Cellular Biochemistry.
[117] I. Mingarro,et al. Peptides derived from apoptotic Bax and Bid reproduce the poration activity of the parent full-length proteins. , 2005, Biophysical journal.
[118] S. Korsmeyer,et al. A stapled BID BH3 helix directly binds and activates BAX. , 2006, Molecular cell.
[119] W. Arap,et al. The neovasculature homing motif NGR: more than meets the eye. , 2008, Blood.
[120] R. Weissleder,et al. A mitochondrial targeted fusion peptide exhibits remarkable cytotoxicity , 2006, Molecular Cancer Therapeutics.
[121] R. Meadows,et al. X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death , 1996, Nature.
[122] A. Schroit,et al. Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. , 1997, Blood.
[123] David A. Cheresh,et al. Integrins in cancer: biological implications and therapeutic opportunities , 2010, Nature Reviews Cancer.
[124] P. Comfurius,et al. Regulatory Mechanisms in Maintenance and Modulation of Transmembrane Lipid Asymmetry: Pathophysiological Implications , 1996, Lupus.
[125] Vladimir P Torchilin,et al. Multifunctional PEGylated 2C5-immunoliposomes containing pH-sensitive bonds and TAT peptide for enhanced tumor cell internalization and cytotoxicity. , 2012, Journal of controlled release : official journal of the Controlled Release Society.
[126] Jason L. Townson,et al. Ineffectiveness of Doxorubicin Treatment on Solitary Dormant Mammary Carcinoma Cells or Late-developing Metastases , 2003, Breast Cancer Research and Treatment.